Amyris (NASDAQ:AMRS) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Tuesday.
AMRS has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Amyris in a research note on Thursday, January 18th. B. Riley set a $10.00 target price on Amyris and gave the stock a “buy” rating in a research note on Tuesday, March 20th. Zacks Investment Research raised Amyris from a “sell” rating to a “hold” rating in a research note on Tuesday, March 13th. Finally, ValuEngine cut Amyris from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Amyris has a consensus rating of “Buy” and a consensus target price of $8.19.
AMRS stock opened at $6.45 on Tuesday. The company has a quick ratio of 0.82, a current ratio of 0.92 and a debt-to-equity ratio of -0.78. The firm has a market cap of $308.02, a price-to-earnings ratio of -2.11 and a beta of 0.12. Amyris has a 52-week low of $1.86 and a 52-week high of $10.65.
Amyris (NASDAQ:AMRS) last posted its earnings results on Thursday, March 15th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.24). The business had revenue of $80.59 million during the quarter, compared to the consensus estimate of $68.14 million. The firm’s revenue was up 262.4% compared to the same quarter last year. During the same period last year, the business posted ($0.09) earnings per share. equities research analysts anticipate that Amyris will post -0.59 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of AMRS. Creative Planning acquired a new stake in shares of Amyris in the fourth quarter valued at $188,000. Hudson Bay Capital Management LP acquired a new stake in shares of Amyris in the fourth quarter valued at $451,000. Finally, Compagnie Lombard Odier SCmA grew its stake in shares of Amyris by 60.0% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock valued at $390,000 after buying an additional 39,000 shares in the last quarter. 22.27% of the stock is owned by institutional investors and hedge funds.
WARNING: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/17/amyris-amrs-downgraded-by-bidaskclub.html.
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.